Facebook Icon Print Created with Sketch. Twitter Icon Created with Sketch. Created with Sketch. LinkedIn Icon Green Check Icon Created with Sketch. YouTube Icon Right Arrow Icon Mobile Menu Icon Chevron Right Icon Phone Icon Health Study Area: AutoImmune Disease Health Study Area: Blood Cancer Health Study Area: Cardiovascular Disease Health Study Area: Fibrosis Health Study Area: Gastrointestinal Cancer Health Study Area: Genitourinary Health Study Area: Head and Neck Cancer Health Study Area: Lung Cancer Health Study Area: Melanoma Health Study Area: Women's Cancer Health Study Area: Breast Cancer For Caregivers For Clinicians Communities FAQs For Parents For Patients Chevron Icon Bookmark Icon Map Icon Share Icon Direction Arrow Icon Direction Arrow Icon Page Icon Location Icon Search Icon External Link Icon Help Icon Error Icon Glossary Email Icon Gender Both Gender Male Gender Female Created with Sketch. Created with Sketch.

Please Log In/Join Now first, and then use this function!

Recruiting

A Safety and Efficacy Study of CC-90011 in Subjects With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas - CC-90011-ST-001

Updated: 8 March, 2021   |   ClinicalTrials.gov

Print Friendly Summary

CONSIDERING THIS TRIAL?
Print this page and the trial guide to help you talk with your doctor.
Use the Study Participant's Guide to navigate the process of participating in a clinical trial. Understand key factors to consider before deciding and get questions to ask your healthcare team.

Trial Details

  • Phase 1

    Phase

  • Gender(s)

  • 18+

    Age Range

  • 8

    Location(s)

  • Recruiting

Treatment Options

Study Arms
ASSIGNED INTERVENTION
Experimental: CC-90011 Administration
Drug: CC-90011

Key Eligibility Criteria

Inclusion Criteria: Subjects must satisfy the following criteria to be enrolled in the study: 1. ≥ 18 years of age 2. Part A: - Subjects with histological or cytological confirmation of advanced unresectable solid tumors (including Grade 2 neuroendocrine neoplasms (NENs)/ neuroendocrine tumors (NETs), small cell lung cancer (SCLC), and other neuroendocrine carcinomas (NECs)) or R/R Non-Hodgkin's lymphomas (NHL) (diffuse large B cell lymphoma (DLBCL) and follicular lymphoma (FL) or marginal cell lymphoma MZL)) 3. Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L without growth factor support for 7 days (14 days if subject received pegfilgastrim) - ANC ≥ 1.0 x 10^9/L (Part B, NHL cohort) 4. Hemoglobin (Hgb) ≥ 10 g/dL (≥ 100 g/L or > 6.2 mmol/L) 5. Platelet Count - Platelet count (plt) ≥ 100 x 109/L (≥ 50 x 10^9/L for NHL subjects) or ≥ 75 x 10^9/L for HCC or NEHCC subjects with portal hypertension without transfusion for 7 days (Part A). - Platelet count (plt) ≥ 150 x 10^9/L (Part B, solid tumor cohort in particular NET and CRPC). - Platelet count (plt) ≥ 50 x 10^9/L (Part B, NHL cohort) 6. Part B: Neuroendocrine tumors: Subjects with histological or cytological confirmation of advanced unresectable solid tumors (including low/intermediate-grade lung NETs, and Prostrate NECs (NEPCs)) which fall under one of the following categories: B) Lung NETs: Subjects with demonstrated tumor progression in the last 12 months on last prior therapy assessed by CT/MRI scan in the following 2 histologies. i. Typical carcinoid (TC) ii. Atypical carcinoid (AC) C) Prostate NECs (NEPCs): 1. Appropriate pathological features according to WHO classification 2. Expression of neuroendocrine markers 3. Mitotic count ≥ 2 -10 per 10 HPF or ≥ 2-10 per 2mm2 and/or ≥ 3% Ki67 index (if reliably available) D) R/R NHL: Subjects with MZL (including EMZL, SMZL, NMZL and histologic transformation of MZL),relapsed/refractory after ≥2 prior therapies and ineligible for potentially curative therapy with the adequate immunohistochemistry markers. Local therapy such as surgery, radiotherapy accounts for a first line treatment. Regarding gastric EMZL, antibiotics only does not count for one line of treatment. Prior therapies must contain at least one prior line with anti-CD20 antibody. Subjects must have progressed on (or not been able to tolerate due to medical comorbidities or unacceptable toxicity), or following standard anticancer therapy or for whom no other approved conventional therapy exists or is acceptable Exclusion Criteria: The presence of any of the following will exclude a subject from enrollment: 1. Low grade (G1) neuroendocrine tumors (<2 per high power fields (HPF) or < 2 per mm2 and/or ≤ 2% Ki67 index) such as carcinoid are excluded. 2. Subject has received anti-cancer therapy (either approved or investigational) ≤ 4 weeks or 5 half-lives, whichever is shorter, prior to Cycle 1 Day 1. - < 42 days for prior nitrosureas or mitomycin C 3. Toxicities resulting from prior systemic cancer therapies must have resolved to ≤National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 prior to starting CC-90011 treatment (with exception of grade 2 peripheral neuropathy and alopecia). 4. Prior autologous stem cell transplant ≤ 3 months before first dose or those who have not recovered. 5. Prior allogeneic stem cell transplant with either standard or reduced intensity conditioning. 6. Subject has undergone major surgery ≤ 4 weeks or minor surgery ≤ 2 weeks prior to Cycle 1 Day 1 or who have not recovered from surgery. 7. Subject has completed any radiation treatment < 4 weeks prior to Cycle 1 Day 1 or < 2 weeks for palliative bone radiotherapy (single fraction). Subjects with > 25% of myelopoetic BM radiation are not allowed to be enrolled on this study. 8. Subject has persistent diarrhea due to a malabsorptive syndrome (such as celiac sprue or inflammatory bowel disease) ≥ NCI CTCAE Grade 2, despite medical management), or any other significant GI disorder that could affect the absorption of CC-90011. 9. Subject with symptomatic or uncontrolled ulcers (gastric or duodenal), particularly those with a history of and/or risk of perforation and GI tract hemorrhages. 10. Subject with any hemorrhage/bleeding event > CTCAE Grade 2 or haemoptysis > 1 teaspoon within 4 weeks prior to the first dose 11. Symptomatic and untreated or unstable central nervous system (CNS) metastases as per protocol. 12. Subject with SCLC that has history of interstitial lung disease (ILD) OR a history of pneumonitis that has required oral or Intra Venous (IV) steroids 13. Subject has known symptomatic acute or chronic pancreatitis. 14. Subject has impaired cardiac function or clinically significant cardiac diseases, as per protocol. 15. Subject has other clinically significant heart disease such as congestive heart failure requiring treatment or uncontrolled hypertension (blood pressure ≥ 160/95 mm Hg). 16. Subject is a pregnant or nursing female. 17. Subject has known Human immunodeficiency virus (HIV) infection. 18. Subject has known chronic active hepatitis B or C virus (HBV, HCV) infection. 19. Subject with ongoing treatment with chronic, therapeutic dosing of anti-coagulants (eg, warfarin, low molecular weight heparin, Factor Xa inhibitors, thrombin antagonist). Low dose low molecular weight heparin for catheter maintenance and for short-term prophylaxis for subjects with prior PE and DVT are permitted under careful consideration by the Investigator. 20. Subject has a history of concurrent second cancers requiring active, ongoing systemic treatment. 21. Subject has any significant medical condition (eg, active or uncontrolled infection or renal disease), laboratory abnormality, or psychiatric illness that would prevent the subject from participating (or compromise compliance) in the study or would place the subject at unacceptable risk if he/she were to participate in the study. 22. Subjects with poor bone marrow reserve as assessed by Investigator such as in the following conditions of (Part B only): - Having received extensive bone radiotherapy - Having experienced several episodes of bone marrow aplasia in previous treatments - Confirmed histological bone marrow cancer infiltration - Requiring regular hematopoietic support (blood transfusion, erythropoietin, GCSF).) 23. Subject has any condition that confounds the ability to interpret data from the study. 24. Previous SARS-CoV-2 infection within 10 days for mild or asymptomatic infections or 20 days for severe/critical illness prior to C1D1. • Acute symptoms must have resolved and based on investigator assessment in consultation with the Medical Monitor, there are no sequelae that would place the subject at a higher risk of receiving study treatment. 25. Previous SARS-CoV-2 vaccine within 14 days of C1D1.

We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information

Have questions? Live support is available 24/7 - Call 855-907-3286 or email clinical.trials@bms.com

Have questions? Live support is available 24/7 -
Call 855-907-3286 or email clinical.trials@bms.com